Depression Resources – Myself

Overview

Perhaps you cannot remember the last time you felt consistently well. You get through work, answer messages, buy groceries and sometimes even laugh with friends, but much of life feels muted or strangely hard. Things that should be enjoyable bring little pleasure. An ordinary task can require an enormous effort to begin. You may wake up already exhausted, or lie awake knowing tomorrow will feel the same.

Some people feel deeply sad. Others are not especially sad at all: they feel empty, flat, slowed down or cut off from enthusiasm. You might still know that you love someone without feeling much warmth; want a successful career without being able to summon motivation; or recognise that you have a good life without being able to enjoy it. You may privately envy how easily other people get excited, recover from disappointment or simply get out of bed. Being told to think positively can feel almost insulting when the problem is that your mind and body are not producing the response you want.

This page is about chronic depression: depression that remains in the background for years, or repeatedly returns over a substantial part of your life, rather than ordinary distress following bereavement, financial problems or another identifiable crisis. External events can still trigger or intensify symptoms in someone with an underlying biological susceptibility. The distinction is not between a “real” illness and human reactions to life; it is whether an enduring vulnerability keeps affecting how you function.

The biological evidence is substantial. Depression is highly polygenic. A major 2025 study involving almost 689,000 people with depression identified 697 genetic associations and implicated brain-cell communication, synapses and other biological pathways. Other studies now connect higher inherited risk with persistent symptoms and recurrence. Brain imaging, blood-metabolite measurements, immune markers and sleep–circadian studies reveal different biological patterns among people given the same depression label. These are promising directions for personalised medicine, although most proposed subtypes do not yet come with a validated treatment-matching test (large genetic study, 2025; longitudinal genetic-risk study, 2025).

The important practical point is that you may be struggling with motivation, pleasure, energy, attention and emotional regulation as biological functions, not merely with an attitude. Good treatment should address those functions and your ability to live the life you want. Meaningful recovery is achievable for many people; some need several treatment approaches, ongoing care or a long-term plan for preventing relapse. You deserve to know what has actually been shown to help.

On this page: Early warning signs · How to get diagnosed? · Life trajectory · Things you might need to work on · Workplace success · Family dynamics · Friendship & social skills · Intimate relationships · Self-help & coping · How it can be for Them to interact with You · Learn more (the Science) · Organisations · Resources · Other people like you

Early warning signs

When depression has been present for a long time, it can become difficult to recognise because you assume this is simply how you are. Signs worth taking seriously include:

• Pleasure has faded. Food, music, sex, friendship, holidays, achievements or hobbies still seem like things you should enjoy, but the feeling does not arrive—or disappears almost immediately.
• Starting things is disproportionately hard. You can see what needs doing but cannot generate the momentum to begin. Other people may interpret this as procrastination or laziness.
• Your energy feels unreliable. Sleep does not restore you; getting dressed, answering an email or making dinner may exhaust you. Some people also experience physical heaviness or noticeably slower movement.
• Your thoughts turn negative by default. You replay mistakes, anticipate failure, assume people are disappointed in you, or struggle to imagine a better future even when circumstances improve.
• Concentration and memory suffer. Reading takes several attempts, decisions feel impossible, and you forget details or lose your train of thought. This can resemble ADHD or cognitive decline.
• Sleep, appetite or daily rhythms change. You might wake very early, sleep excessively, become a night owl, lose interest in food or seek comfort from it. Patterns differ between people.
• You become irritable or emotionally distant. Other people’s enthusiasm, requests or normal problems can feel overwhelming. You may snap, withdraw or have little attention left for anyone else.
• You stop reaching out. Invitations, texts and friendships begin to feel like obligations. You may miss people but still be unable to respond.
• Your achievements feel undeserved or irrelevant. Praise barely registers; setbacks confirm your worst thoughts about yourself. You may keep working hard while feeling empty inside.
• You have thoughts of disappearing or not being alive. These deserve prompt attention, especially if they become more frequent, specific or difficult to resist. Seek urgent professional help when you cannot keep yourself safe.

Depression can coexist with anxiety, ADHD, autism, chronic pain, substance problems or physical illness. Some people appear highly successful while carrying a considerable symptom burden. What matters is not whether you can occasionally smile or function, but what life repeatedly costs you.

How to get diagnosed?

You do not need to spend years talking before you can get useful help. A good assessment starts with your actual experience: How long have you felt this way? Is it constant or recurrent? What has changed in pleasure, energy, sleep, thinking, work and relationships? What treatments have you tried, and what happened?

A clinician can explore the pattern over time, use short symptom questionnaires to establish a baseline, and ask about your physical health, medications and other mental-health conditions. An important question is whether you have ever had periods of unusually elevated energy, reduced need for sleep or markedly changed behaviour. That may point towards bipolar-spectrum illness, for which treatment planning differs.

It is also reasonable to investigate possible contributors such as thyroid problems, anaemia, vitamin deficiencies when relevant, sleep apnoea, medication effects or other medical conditions. These tests may discover a treatable contributing illness; they are not generic blood tests that prove or disprove chronic depression.

There are already measurable depression-associated differences in genetic risk, brain activity, inflammatory signalling, blood metabolites and circadian rhythms. Researchers have even developed AI models that identify candidate brain and metabolic subtypes. These are real research findings, but most are not yet validated for diagnosing one person or selecting their ideal antidepressant. Pharmacogenetic information about how your body metabolises certain medicines is a more immediate, though narrower, clinical application.

Ask your clinician: What pattern best describes my depression? What else could contribute? Which outcomes should improve? What is our next step if the first treatment does not work? A useful assessment should lead to a treatment plan and a way to measure progress.

Life trajectory

For some people, depression starts so early that they grow up believing they are naturally tired, pessimistic, shy or unmotivated. Others have repeated episodes separated by periods of feeling well. A person may recover from one episode only to become depressed again years later. Duration, recurrence, severity and age of onset all matter, and research increasingly suggests that these patterns differ partly in their genetics and biology.

Untreated or poorly controlled chronic depression can accumulate costs. Education becomes harder when concentration and motivation repeatedly disappear. Promotions may pass you by because you lack energy to compete for them. Friendships fade. Relationships may end when your partner feels alone, unwanted or responsible for keeping everything going. You might earn less, postpone having children, spend money trying to feel better, or lose confidence in your ability to change direction.

These outcomes are not inevitable. Effective treatment may make ordinary functioning less effortful, restore enjoyment, improve concentration and sleep, and allow you to sustain work and relationships. Remission is possible, but chronic depression often benefits from ongoing review, relapse prevention and more than one treatment attempt. If something has not worked, that is a reason to reassess the approach, not evidence that all treatment is pointless.

There are also physical-health implications. A 2025 study combining information about blood proteins, gene regulation and biological ageing found that people with a history of major depression showed signs of accelerated biological ageing in two population cohorts. The association was weaker among people with evidence of remission. This is important, but it cannot tell you how many years depression will shorten your life, and the study did not isolate chronic depression from every other presentation (Diniz and colleagues, 2025).

If you have thoughts of suicide, or begin to feel that people would be better off without you, tell someone you trust and seek clinical support. If you might act on those thoughts, contact local emergency services or urgent mental-health care. The worst days are not the right time to make irreversible decisions.

Things you might need to work on

Chronic depression can take away the energy needed to recover. That makes simple advice such as “just exercise” or “get out more” frustratingly incomplete. A workable plan starts with what you can actually do now.

• Treat the loss of motivation as a symptom worth addressing. Do not wait until you feel enthusiastic before taking every small step. Sometimes action precedes the feeling; sometimes symptoms are too severe and treatment needs changing first.
• Make tasks smaller than your pride would prefer. Showering, preparing one meal, opening one document or walking outside for a few minutes are real achievements when functioning is severely impaired. You can increase the challenge as capacity returns.
• Notice thought patterns without accepting them as facts. “Nothing will ever change” may feel completely convincing during an episode. Record what actually happens over time, including days that contradict it.
• Build a treatment plan you can follow. Appointments, medication schedules, sleep routines and small activities are easier with reminders or help from someone you trust.
• Watch for isolation. Depression can make other people feel distant or tiring, even when you love them. A short honest message is often enough to preserve a connection.
• Keep your own wishes visible. Your life is not only about managing symptoms. Ask what you would like to do if pleasure, concentration and energy returned—and make those outcomes part of treatment goals.
• Be fair to the people around you. Depression can narrow your attention to your own suffering. You may have little emotional bandwidth, but partners, children and friends still have needs. You can acknowledge theirs without pretending to feel better than you do.
• Take repeated treatment failures seriously. Ask whether the diagnosis, dose, duration, side effects, coexisting conditions or treatment mechanism should be reviewed. You are entitled to a thoughtful next step.

You do not have to become cheerful or endlessly productive. The aim is to regain freedom: to care about things, make decisions, feel connected and enjoy parts of your life again.

Workplace success

You may be capable, conscientious and intelligent while finding work extraordinarily draining. Depression can interfere with planning, attention, memory, speed, confidence and the sense that effort leads to reward. You might work twice as hard to produce what used to come naturally, miss deadlines because you cannot start, or turn down opportunities because the thought of extra responsibility feels unbearable.

Some people become remarkably good at hiding depression. They perform well in meetings, then spend evenings recovering. Colleagues may assume everything is fine because the visible results are acceptable. Others notice reduced output, withdrawal or mistakes and misinterpret these as lack of commitment.

Try to distinguish between problems with the job itself and problems that follow you across different settings. If work that once interested you now feels pointless, that is useful information for your treatment plan. Practical adjustments can include clearer priorities, predictable hours, fewer unnecessary interruptions, protected recovery time, and a realistic workload during a difficult period. Whether to disclose your health condition is a personal decision, influenced by workplace rules and your circumstances.

It can be especially discouraging to watch less-qualified colleagues progress while you are struggling just to maintain your position. You have not necessarily lost your abilities. Recovery may allow you to use them more consistently. When possible, measure improvement through actual functioning—hours you can concentrate, tasks completed, days missed, confidence returning—not only whether you feel less sad.

Family dynamics

Chronic depression affects a household even when nobody talks about it. You may be physically present but emotionally hard to reach, need more help with chores or appointments, and struggle to share other people’s excitement. Family members may respond with concern, frustration, anger or excessive attempts to cheer you up.

If you are a parent, depression can make play, patience and ordinary routines hard. A child may worry that your withdrawal is their fault. Simple, age-appropriate reassurance and dependable support from other adults can help protect them. Children should not become responsible for keeping a parent alive or emotionally stable.

If you are an adult child or sibling, relatives may expect you to “snap out of it,” take a conventional career path or attend family events you cannot manage. Some may genuinely misunderstand how severely depression affects energy and pleasure. It can help to explain particular limits: “I want to come, but two hours is realistic for me,” or “Please help me book an appointment rather than telling me to be positive.”

If you depend heavily on a partner or parent, try to preserve whatever independence is possible. Ask for practical help, but keep an eye on whether one person has become your entire social life, therapist and source of motivation. Everyone involved needs rest and support.

Friendship & social skills

Depression can make friendship feel like something you are failing at. You forget birthdays, cancel at the last minute, stop replying to messages or disappear for weeks. You may genuinely miss people yet feel unable to face them. Friends can interpret silence as indifference, rejection or a sign that they have done something wrong.

Other people’s enthusiasm may seem strangely distant. Someone tells you wonderful news and you know you should be delighted, but you cannot produce the feeling. A friend complains about something small and you find yourself thinking, How can that matter when everything feels this difficult? That narrowed perspective can damage relationships, even when you do not intend to hurt anyone.

You do not need to manufacture excitement. A simple “I’m glad this happened for you; I’m struggling to show it right now” can still be meaningful. Tell close friends what helps: a walk instead of a loud party, short visits, practical invitations, or messages that do not require an immediate response.

Some friendships will fade. People may feel hurt by repeated cancellations or the lack of reciprocity. You may not be able to repair every connection, but treatment and small acts of attention can prevent chronic depression from quietly taking your whole social world away.

Intimate relationships

Being loved does not necessarily make depression disappear. You may have a kind, attractive, devoted partner and still feel emotionally numb, uninterested in sex, exhausted by conversation or unable to look forward to shared plans. That can be frightening: you may wonder whether you have fallen out of love, when the loss of pleasure extends to almost everything.

Your partner may feel unwanted or become the person who initiates affection, organises the household and makes all the decisions. They may try hard to help and then become resentful when nothing seems to work. From your side, repeated advice or reassurance can feel like pressure to perform happiness for someone else’s comfort.

Honesty helps more than pretending. Explain what is happening as specifically as you can: “I care about you, but my ability to feel pleasure is very low right now,” or “I need affection without pressure for sex.” If an antidepressant affects sexual function or emotional responsiveness, discuss it with the prescriber rather than assuming this is an unavoidable price of treatment.

It also matters that your partner remains a person with needs of their own. Depression may explain withdrawal, irritability or reduced attention; it does not make repeated cruelty, control or neglect harmless. Couples may benefit from practical agreements and, where appropriate, professional support alongside treatment for the depression itself.

Good relationships can survive long periods of depression. But some become unequal or end, particularly if symptoms remain severe and neither person can see a way forward. A treatment plan that restores emotional connection and everyday functioning is often as important as reducing the number on a depression questionnaire.

Self-help & coping

The strongest approach is usually to combine appropriate professional treatment with changes that support sleep, activity, relationships and daily functioning. The balance depends on severity, previous treatment, other conditions and what you can tolerate.

Treatments with established evidence

Psychological therapies. Cognitive behavioural therapy (CBT) and other structured therapies can help with persistent rumination, hopeless predictions, avoidance, withdrawn behaviour and relationship difficulties. CBASP is a form of psychotherapy developed specifically for chronic depression, focusing particularly on interpersonal consequences and repeated patterns. These are active treatments, not years of talking without agreed goals. If progress is limited, review the approach.

Antidepressant medication. SSRIs, SNRIs and several other medication classes help some people substantially. Different medicines affect different signalling systems and side-effect profiles, and the first choice may not be the best one for you. Ask what improvement to expect, when to review it, and what alternatives exist. Do not stop or switch prescribed medication abruptly without medical advice.

Combination treatment. Therapy and medication together can be especially useful when depression is persistent, severe or difficult to manage with one treatment alone. Current guidelines include combinations, but no single plan is best for everyone (NICE chronic-depression guidance).

Specialist treatment when the first approaches fail. Depending on severity and circumstances, options include changing or adding medication, repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), or medically supervised ketamine/esketamine. ECT is particularly relevant to some severe presentations, and rTMS offers a non-surgical way to influence brain circuits. These require individual assessment, access and monitoring; treatments that help one person may not help another.

Approaches that can help alongside treatment

Exercise—including walking, strength training and yoga—has meaningful evidence for reducing depressive symptoms in broader depression studies. If you can barely get out of bed, begin at a level that is physically and emotionally realistic. An activity that is possible three times a week is more useful than an ambitious plan you cannot start.

Sleep and circadian routines are worth examining carefully, particularly if you routinely sleep very late, feel exhausted on waking, or have pronounced seasonal changes. More recent genetic research suggests that some people with depression have a distinctive circadian-associated profile. Regular sleep timing, morning light or other targeted measures may be useful when clinically appropriate, but the new proposed subtype has not yet been shown to respond better to one particular intervention.

Social contact, practical help, mindfulness and relaxation can reduce isolation or stress and make treatment easier to maintain. They do not replace effective care for severe depression. Alcohol and recreational drugs can complicate sleep, mood and medication safety, even when they seem to provide short-term relief.

Promising, experimental or poorly supported approaches

Psilocybin-assisted therapy has produced encouraging results in some controlled studies of depression and treatment-resistant depression, including a 2026 trial conducted in a public healthcare setting. Another 2026 trial did not meet its main outcome, however. This is active research, not evidence that self-administered mushrooms are a safe or reliable treatment. Studies use screening, controlled dosing, psychological support and monitoring. Psychedelics can trigger serious adverse reactions, particularly in people vulnerable to mania or psychosis.

Anti-inflammatory medicines, hormones, supplements, microbiome treatments and commercial “brain rewiring” programmes are all discussed online. Some have plausible biological rationales, and some may benefit a separately identified medical problem. None has established universal effectiveness for chronic depression based on a personalised biomarker profile. Be wary of anyone who promises a cure after measuring one gene, cortisol result, microbiome pattern or brain scan.

Know whether a treatment is helping

Choose two or three outcomes that matter to you: enjoyment returning, getting out of bed more easily, better concentration, fewer lost working days, reconnecting with a friend or feeling affection again. Record them occasionally, alongside sleep and side effects. If a treatment does not produce a useful change within an agreed review period, discuss what to adjust. The aim is a more liveable life, not simply a better score.

How it can be for Them to interact with You

Other people may find it difficult to understand how much effort ordinary life requires from you. They see someone who has reasons to be happy but rarely seems pleased, turns down invitations, struggles to start tasks or responds irritably to well-meant suggestions. They may feel helpless, rejected, worried or eventually exhausted themselves.

You might experience them as demanding, superficial or painfully cheerful. Their advice can sound as though they believe you have simply failed to try. Sometimes you may become so focused on your own exhaustion and pain that you overlook the effect of your silence, pessimism or anger on them.

It can help to tell people what is happening, what is useful and what is not. “I don’t need you to solve it; sitting with me helps.” “Please invite me even if I often say no.” “I can manage one task today, not five.” “If I become irritable, you can tell me, and I will try to step back.”

People close to you are not responsible for curing your depression. They can support treatment, offer practical help and maintain a relationship, but they also need boundaries, friendships and rest. You deserve understanding, and they deserve to have their experiences taken seriously. Protecting that balance can make support more sustainable for everyone.

Learn more (the Science)

What “chronic depression” means in research

This page covers long-lasting depressive symptoms and recurrent depression over years rather than short-lived, understandable distress. Research definitions vary: studies may recruit people with persistent depressive disorder, chronic major depression, recurrent episodes, treatment-resistant depression or general major depression. These populations overlap but are not interchangeable. In particular, most large GWAS, metabolomic and neuroimaging studies are of major depression broadly, rather than a biologically defined subset of people whose depression has been continuous for years. Findings below are labelled accordingly.

“Chronic” describes course, not a single molecular cause. Environmental and developmental influences can interact with inherited susceptibility; excluding a recent life event does not establish a particular biological subtype. An important goal for precision medicine is longitudinal measurement of symptoms, functioning and biology, rather than relying on a one-time questionnaire alone.

Polygenic architecture, candidate genes and recurrence

Twin and family evidence has historically estimated the heritable contribution to broad major-depression risk at approximately 37% (95% CI 31–42% in a pooled twin-study estimate). The much stronger contemporary evidence about specific molecular pathways comes from genome-wide studies rather than isolated candidate-gene reports (Sullivan and colleagues, 2000).

The 2025 trans-ancestry Cell GWAS combined 688,808 cases and 4,364,225 controls from 29 countries, identifying 697 independent associations at 635 loci, including 293 novel associations and 308 high-confidence gene associations from combined prioritisation methods. Single-cell and functional analyses implicated excitatory and inhibitory neurons, medium spiny neurons, postsynaptic density and receptor clustering. A polygenic score accounted for up to 5.8% of depression liability variation in Europeans; this is a modest predictive fraction and is not an individual diagnosis (Psychiatric Genomics Consortium, 2025).

Concrete biological leads include DRD2, which encodes a dopamine receptor relevant to reward signalling; CYP7B1, involved in neurosteroid metabolism; and fine-mapped regions near FURIN and ESR1. Earlier large-scale analyses also implicated glutamate- and GABA-receptor biology, glial lineages and developmental neural pathways. Gene prioritisation is not the same as proving that a particular variant causes depression. Historically prominent single candidates such as SLC6A4/5-HTTLPR, BDNF Val66Met and COMT Val158Met should not be presented as dependable explanations of an individual’s chronic depression (2025 genomic study; 2023 genomic study).

There is specific evidence linking common genetic burden with course. In a 2025 prospective cohort of 12,029 older adults, each standard-deviation increase in a depression polygenic score was associated with higher odds of a persistent high-symptom trajectory versus a low-symptom trajectory (OR 1.40; 95% CI 1.31–1.49). The cohort’s age and European ancestry limit generalisation (Shen and colleagues, 2025). A 2023 Nature Medicine analysis of over 1.3 million participants also linked genetic burden with recurrence and psychiatric comorbidity (Als and colleagues, 2023).

Depression beginning at different ages may not share exactly the same genetic architecture. A 2025 Nordic biobank study included 46,708 early-onset and 37,168 late-onset cases and estimated their genetic correlation at 0.58, with differing associations with developmental and other psychiatric traits. This supports finer stratification, but age of onset is not itself a validated mechanism or treatment selector (2025 Nature Genetics study).

Brain circuits, neuroimaging and machine learning

A 2024 Nature Medicine study used task-based and resting-state functional MRI in 801 people with depression or anxiety, identifying six brain-circuit biotypes related to attention, emotional processing, cognitive control and other functions. In a smaller randomised treatment component (n = 250), biotypes differed on some treatment-response measures. Some subgroup/treatment cells were small, so the study is a proof of concept for circuit-guided stratification, not a validated clinical algorithm for selecting medication from one MRI scan (Tozzi and colleagues, 2024).

A 2025 multiomics study analysed 327 people with major depression and 480 controls. Imaging-derived subtypes were investigated with genetic, epigenetic, metabolic and inflammatory measurements. One subtype showed stronger genetic signals related to synaptic and neuronal development, together with more severe symptoms and cognitive impairment; another had an inflammatory profile involving IL-1β and associated molecular changes; a third lacked a clear molecular signature. These findings need external replication and trials demonstrating that subtype-matched treatment works better (Tang and colleagues, 2025).

EEG and MRI connectivity measurements may also predict responses to rTMS in selected datasets, but systematic examinations of reproducibility show that clinical translation requires larger, independently validated models and proof that acting on a prediction improves outcomes (review of MRI/EEG biomarkers, 2024).

Metabolomics, inflammation, hormones and circadian biology

In December 2025, a PLOS Digital Health study profiled 249 blood metabolites from 7,945 people with current depression in UK Biobank. Machine-learning analysis distinguished three profiles: fatty-acid dysregulation, an intermediate phenotype and a hyperlipidaemic phenotype. Subtype-classification approaches were tested in the independent Whitehall II cohort and outperformed a simple binary classification in that study. However, the metabolic subtypes were not distinguished by significant SNP associations in the analysis, and treatment selection was not tested. These are promising blood-based phenotypes, not an approved diagnostic panel (Ma and colleagues, 2025).

Immune-related findings include associations involving CRP, IL-6, IL-1β, inflammatory signalling and metabolic abnormalities. Their average effects and predictive value vary. Notably, two recent systematic syntheses reached different conclusions about whether baseline inflammatory markers predict antidepressant nonresponse, reflecting differences in methods, study populations and confounding. CRP can be elevated for many reasons unrelated to depression. At present, no inflammatory threshold reliably selects an individual antidepressant or an anti-inflammatory treatment for chronic depression (2026 meta-analysis; 2026 updated review).

A newly published 20 October 2026 Australian Genetics of Depression Study analysis examined 11,380 participants; 2,604 (23%) met the authors’ proposed circadian depression definition based on combinations of delayed sleep timing, evening preference, seasonality, morning tiredness, hypersomnia and social jetlag. This subgroup had distinct polygenic associations involving sleep, psychiatric, metabolic and inflammatory traits. Self-reported antidepressant response was slightly poorer for SSRIs (OR 0.88; 95% CI 0.82–0.94) and SNRIs (OR 0.89; 95% CI 0.83–0.97). The cross-sectional, self-report design and provisional subtype definition mean circadian-targeted treatment superiority remains untested (Tonini and colleagues, 2026).

These pathways are biologically connected: sleep timing influences endocrine, metabolic and immune processes, while neural reward and cognitive-control systems interact with the body’s energy state. They are not five isolated diseases discovered by one test.

Biological ageing and longer-term health

A 2025 multiomics study using UK Biobank and the Finnish Twin Cohort linked a history of major depression to accelerated systemic and brain-related proteomic ageing and weaker, more variable epigenetic-age signals. Proteomic ageing patterns were associated with incident depression, dementia-related outcomes and mortality in parts of the analysis. Evidence of remission attenuated some associations. Mendelian-randomisation analyses supported a possible causal direction from depression to accelerated proteomic ageing, but such analyses retain assumptions and do not yield an individual’s years of life lost (Diniz and colleagues, 2025).

The implications are important: managing depression may matter for physical health as well as mood. But it would be inappropriate to turn these group-level findings into a prediction of years of life lost or gained for one person. The evidence is about broader major-depression populations and biological markers, not a dependable personalised lifespan calculator.

Treatment evidence and effect sizes

Psychotherapy and conventional medication. NICE recommendations for chronic depressive symptoms include CBT, SSRIs, SNRIs, selected tricyclic medicines, and combination approaches. They specify attention to avoidance, rumination and interpersonal difficulties, with systematic review of inadequate response (NICE NG222). The older but directly relevant 2016 CBASP meta-analysis pooled six randomised studies involving 1,510 patients with chronic depression and found small overall advantages over other treatments or usual care (Hedges’ g approximately 0.34–0.44, depending on the analysis). This is real direct chronic-depression evidence; it is neither a universal cure rate nor proof that every psychotherapy has the same effect (Negt and colleagues, 2016). A 2025 published protocol for a new individual-patient-data network meta-analysis is a plan for future synthesis, not a new effectiveness result (Schramm and colleagues, 2025).

Exercise and yoga. A 2024 network meta-analysis of 218 randomised trials (14,170 participants) in depression broadly reported reductions relative to active controls for walking/jogging (g ≈ −0.62), yoga (g ≈ −0.55) and strength training (g ≈ −0.49), with smaller effects for several other modalities. Confidence in the network estimates was generally low or very low, and the analysis did not establish these effects specifically for lifelong persistent depression. Exercise is a genuine evidence-supported option, but cannot always be implemented without first reducing severe symptoms or physical limitations (Noetel and colleagues, 2024).

Ketamine/esketamine. A 2025 individual-patient-data meta-analysis of seven randomised trials (1,505 patients) of intranasal esketamine in treatment-resistant depression found a mean 2.94-point improvement over placebo on the Montgomery–Åsberg Depression Rating Scale after four weeks when added to antidepressant treatment (95% CI −5.39 to −0.48; standardised mean difference approximately −0.25). A continuation trial reported reduced relapse risk among selected responders (HR 0.38; 95% CI 0.26–0.57), but trial-design concerns complicate interpretation. Sedation (RR 3.70) and dissociation (RR 2.36) were more frequent. A separate 2025 monotherapy RCT was positive, illustrating ongoing development of this treatment class. These are specialist treatments, not proof of effectiveness for every chronic-depression subtype (Naudet and colleagues, 2025; 2025 monotherapy RCT).

Psilocybin-assisted psychotherapy. Results are promising but mixed. A 2023 randomised trial (104 adults with major depression) reported a large benefit of supervised psilocybin with psychological support over an active comparator at six weeks (approximately 12.3 points greater MADRS reduction). In 2026, a small NHS-based randomised feasibility trial (n = 60) reported a large between-group effect at three weeks (approximately −10.4 MADRS points; Cohen’s d −1.70), but its primary purpose was feasibility, and confirmation is needed. In contrast, the 2026 EPISODE trial (n = 144) of treatment-resistant depression did not achieve a statistically significant effect on its primary response endpoint, although some secondary measures favoured psilocybin. Such studies often exclude people with mania or psychosis risk, and blinding is difficult. These findings justify careful research, not self-medication with mushrooms (Raison and colleagues, 2023; Rucker and colleagues, 2026; Mertens and colleagues, 2026).

Brain stimulation. rTMS and ECT have established roles for selected people with depression, particularly when conventional approaches are ineffective or illness is severe. Neuroimaging-based targeting and EEG-guided response prediction are active precision-medicine research areas. There is not yet a universally validated imaging biomarker that assigns every person with chronic depression to their optimal stimulation protocol.

Pharmacogenetics. The 2023 CPIC guideline gives genotype-based prescribing guidance for aspects of antidepressant metabolism involving CYP2D6, CYP2C19 and CYP2B6. It does not support clinical recommendations based on SLC6A4 or HTR2A genotypes because the evidence for treatment selection remains insufficient. A metabolism-related dosing decision is useful precision prescribing; it is not molecular diagnosis or treatment matching to a proven depression subtype (CPIC, 2023).

What would make a future biomarker clinically useful?

For any proposed genetic, blood-based, AI or brain-circuit test, ask: Was the model tested in independent cohorts? Did it distinguish persistent depression from recurrent, bipolar, anxiety-related or medically driven symptoms? Does it predict future functioning or treatment response better than a careful history? Was treatment actually assigned using the test, and did patients do better? Were costs, harms and unequal performance across populations assessed?

Those final steps are where much of depression precision medicine is still developing. The emerging biology is compelling, but the patient’s goals—pleasure, concentration, relationships, work, energy, health and fewer future episodes—must remain the outcomes that matter.

Organisations

• National Institute of Mental Health (US) — research-based information on depression and treatment.
• Mind (UK) — accessible guidance on symptoms, treatments and everyday life.
• Depression and Bipolar Support Alliance (US) — peer support and educational resources; also useful when depression and bipolar-spectrum conditions need distinguishing.
• NAMI (US) — mental-health education, family resources and support programmes.
• World Health Organization — global public-health information on depression.
• NICE (UK) — detailed evidence-based guidance on chronic depressive symptoms and further treatment options.

Availability and eligibility depend on your location. If you might harm yourself or cannot remain safe, seek urgent local professional help rather than waiting for an ordinary appointment.

Resources

Selected primary studies and evidence syntheses supporting this page:

• Genetics and course: 2025 trans-ancestry GWAS: 697 associations; 2023 genomic study of recurrence and comorbidity; 2025 polygenic scores and persistent depressive trajectories; 2025 early- versus late-onset genetics.
• Brain, AI and multiomics: 2024 six brain-circuit biotypes; 2025 imaging plus multiomics subtypes; 2025 blood-metabolite subtypes with external-cohort testing; 2026 proposed circadian subtype.
• Inflammation, genetics and ageing: 2026 review of inflammatory predictors; 2025 multiomics study of biological ageing; 2023 CPIC pharmacogenetics guideline.
• Evidence-based care: NICE guidance for chronic depression; CBASP meta-analysis in chronic depression; 2024 exercise and yoga network meta-analysis; 2025 esketamine individual-patient-data meta-analysis.
• Emerging treatments: 2023 psilocybin RCT; 2026 NHS psilocybin feasibility RCT; 2026 EPISODE trial with negative primary outcome; 2024–2025 EEG/MRI markers for rTMS prediction.

Related biological variations in attention, sleep, anxiety and mood can be explored through Relatix Health Resources. Sharing a clinical label does not mean sharing exactly the same biological mechanisms; equally, a proposed subtype is not yet a clinically proven treatment-matching tool.

Other people like you

You may recognise yourself in someone who keeps a demanding job but spends every evening in bed, a person whose depression began in adolescence and never fully lifted, someone who cycles between productive months and repeated episodes, or a parent who loves their children but feels too exhausted to play. Some people are visibly sad; others are irritable, numb, restless or simply unable to feel enthusiasm.

It can be isolating when people think depression must be a response to something bad happening. You may have loving relationships, opportunities and a safe home and still struggle deeply. You may also find yourself feeling guilty because you know what you have and cannot enjoy it. Being able to explain the biological differences behind depression can make those experiences easier to describe, without pretending that researchers already know every answer.

We would like to understand what has helped people with different long-term patterns: a particular medicine, combination treatment, structured therapy, brain stimulation, changes to sleep timing, exercise, support at work, or something else. Which changes lasted? Did pleasure, relationships and functioning improve, or only a symptom score? What failed, despite promising claims?

Our long-term aim is to connect those lived experiences with genetics, multiomics, brain function and rigorous treatment research, so that people who look similar on a checklist may eventually receive care better matched to their biology and their goals.

If you are at immediate risk of suicide or otherwise unable to keep yourself safe, contact local emergency services or urgent mental-health care.